172P Functional precision medicine assay identifies patients with relapsed/refractory soft tissue sarcoma who benefit from bortezomib-based therapy

20260 citationsJournal Articlehybrid Open Access

Authors

7.5%.Other G1/2: mucositis 37.5%, hyperglycemia 37

Published in: ESMO rare cancers.

Volume 5, pp. 100378-100378

Field-Weighted Citation Impact: 0.00